← All tasks
Task H-005 · Type H — Insufficient evidence (should abstain)
Is there CRISPR-based gene-editing evidence for treating alkaptonuria in the indexed corpus?
Difficulty
medium
Rarity stratum
sparse
Evidence type
insufficient_evidence
MONDO ID
MONDO:0008753
Curator notes
VERIFIED by full-text grep restricted to the 21-document AKU subset (2026-09-07): "crispr" does not appear. Corpus's AKU treatment coverage is limited to nitisinone (a repurposed small-molecule enzyme inhibitor), not gene editing.
Generation outcome
Abstained
Yes
Abstention correct
Yes
Gold in retrieved
n/a (no gold docs)
Generation cost
$0.000219
Claims
0
Supported
0
Contradicted
0
Unverifiable
0
Gold documents (0)
No gold documents — this is an insufficient-evidence (Type H) task; the correct answer is abstention.
Retrieved documents (6)
- Alkaptonuria: Current Perspectives.pubmed:32158253
- Alkaptonuria--case report.pubmed:25184921
- Activation of the imprinted Prader-Willi syndrome locus by CRISPR-based epigenome editing.pubmed:39947136
- Alkaptonuria in Russia: mutational spectrum and novel variants.pubmed:33621656
- Duchenne muscular dystrophy: CRISPR/Cas9 treatment.pubmed:26926391
- Ashy ears.pubmed:20694448
Generated claims (0)
No claims generated — the model abstained on this task.